SCHEMBL5226413

SCHEMBL5226413

CCc1nn(CCO)c(CC)c1Oc1ccccc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.39
POLB P06746 1/20 0.39
PKM P14618 1/20 0.39
ALOX15 P16050 2/20 0.37
ATM Q13315 1/20 0.36
KMT2A Q03164 5/20 0.35
MEN1 O00255 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
RHEB Q15382 1/20 0.35
RARG P13631 1/20 0.34
RORC P51449 1/20 0.34
HPGD P15428 3/20 0.33
ALDH1A1 P00352 3/20 0.33
HSD17B10 Q99714 2/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ESR1 P03372 1/20 0.33
CXCL8 P10145 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5224661 0.88 P2RX7 (0.34) LMNAPOLBPKMALOX15
SCHEMBL5226203 0.87 DHODH (0.38) ATMRARGRORCGAA
SCHEMBL5225100 0.81 MAPK14 (0.37) LMNAALOX15ATMKMT2AMEN1
SCHEMBL5228213 0.78 KDM4E (0.36) ATMRARGRORCHPGDALDH1A1
SCHEMBL5230979 0.77 KCNH2 (0.36)
SCHEMBL5229746 0.77 P2RX7 (0.37) ATMKMT2AMEN1RARGRORC
SCHEMBL5227964 0.77 PTGDR2 (0.42) LMNAATMKMT2AMEN1SMN1; SMN2
SCHEMBL5226171 0.76 FPR2 (0.41) LMNASMN1; SMN2HPGDMAPTMAPK1
SCHEMBL5227746 0.76 PTGDR2 (0.42) LMNARHEBALDH1A1
SCHEMBL5224650 0.74 PGR (0.39) LMNAKMT2ASMN1; SMN2HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100408564-C Pyrazole derivatives for treating HIV PFIZER LTD (US) 2008-08-06 CN claimed
EP-1377556-B1 PYRAZOLE DERIVATIVES FOR TREATING HIV PFIZER LTD (GB) 2007-04-04 EP claimed
EP-1762567-A1 Pyrazole derivatives for treating HIV Pfizer Limited (GB) 2007-03-14 EP claimed
CN-1514828-A Pyrazole derivatives for treating HIV 2004-07-21 CN claimed
EP-1377556-A1 PYRAZOLE DERIVATIVES FOR TREATING HIV Pfizer Limited (GB) 2004-01-07 EP claimed
US-20030100554-A1 Pyrazole derivatives JONES LYN HOWARD (GB) 2003-05-29 US claimed
WO-2002085860-A1 PYRAZOLE DERIVATIVES FOR TREATING HIV PFIZER LIMITED (GB) 2002-10-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100554-A1 Pyrazole derivatives REV1, SARS1, CYP2F1 LMNA 3857/4885POLB 66/4885PKM 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.